Shanghai Universal Biotech Co., Ltd. Class A

Shanghai Universal Biotech Co., Ltd. Class A

SSZSE:301166
27.24
CNY
-0.70
(-2.51%)
-0.18EPS
3.05BMarket Cap
Apr 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.82
2.69
13.82
22.82
7.27
10
12.63
13.1
16.94
13.79
14.29
13.22
12.28
14.34
Basic EPS, GAAP
0.01
0.12
0.51
1.41
0.44
0.66
0.93
1.18
1.66
1.23
0.47
0.12
-0.26
-0.18
Free Cash Flow per Basic Share
0.09
-0.15
-0.76
0.85
0.3
0.34
0.07
1.35
0.68
-2.36
-1
0.06
-0.49
- -
Dividend per Share
0.01
0.01
0.06
0.07
0.02
- -
0.33
0.01
0.31
0.51
0.92
0.48
0.23
0.02
Book Value per Share
0.29
0.41
0.98
1.33
2.52
3.19
5.07
6.23
24.1
24.89
24.43
23.86
23.14
22.62
Tangible Book Value per Share
0.29
0.41
0.98
1.33
2.52
3.19
5.05
6.21
24.02
24.81
24.33
23.74
23.04
22.53
Basic Weighted Avg Shares
60
60
17
15
59
60
62
65
65
87
86
85
88
85
Sales/Revenue/Turnover
109
162
232
342
432
604
787
849
1,110
1,195
1,226
1,118
1,084
1,223
Operating Margin (%)
2.11
6.71
5.69
8.24
8.15
9.32
10.16
11.32
12.44
8.79
1.25
-2.28
-3.87
-3.17
Depreciation Expense
1
1
1
2
3
3
4
6
7
12
19
22
25
- -
Net Income, GAAP
1
7
9
21
26
40
58
76
109
107
40
10
-23
-15
Effective Tax Rate (%)
35.86
25.47
22.16
22.91
26.42
21.11
21.28
20.11
21.01
17.05
- -
- -
- -
- -
Profit Margin (%)
0.59
4.43
3.69
6.18
6.05
6.6
7.36
9.01
9.8
8.92
3.29
0.91
-2.12
-1.27
Working Capital
11
15
39
57
121
155
289
365
2,037
2,014
1,848
1,715
1,584
1,409
LT Debt
4
2
11
7
- -
- -
- -
- -
5
23
23
11
5
8
Total Equity
17
24
59
80
151
191
329
405
2,088
2,157
2,117
2,068
2,006
1,949
Return on Invested Capital (%)
- -
22.72
13.73
19.84
20
27.56
27.3
24.55
8.98
4.93
- -
- -
- -
- -
Return on Capital (%)
- -
27.35
17.19
23.32
21.29
23.26
21.62
19.72
8.68
4.95
- -
- -
- -
- -
Return on Common Equity (%)
- -
34.26
20.63
30.58
22.63
23.28
22.25
20.84
8.72
5.02
1.89
0.49
-1.13
-0.78

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
74
60
80
LT Borrowings
- -
- -
- -
LT Finance Leases
4
8
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
87
86
86
Market Capitalization
2,613
2,222
3,046

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,803
1,736
1,740
Cash, Cash Equivalents & STI
1,207
1,067
1,068
Accounts Receivable, Net
405
432
459
Inventories
145
150
149
Total Current Liabilities
279
301
331
Payables & Accruals
- -
- -
- -
ST Debt
74
60
80
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
65.95%
82.4%
-3%
Free Cash Flow
-1.38%
-357.01%
-1,014.66%
Net Income, GAAP
-12.24%
-84.59%
-326.12%
Sales/Revenue/Turnover
18.09%
5.82%
-3.05%
Total Cash Common Dividend
1,394.38%
1,056.81%
-50.92%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
272
281
275
290
1,118
2025
216
288
- -
308
1,084
2026
259
309
347
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.11
-0.01
-0.05
0.12
2025
-0.07
-0.08
- -
-0.09
-0.26
2026
-0.1
-0.04
0.05
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.48
2025
- -
- -
- -
0.01
0.23
2026
- -
- -
- -
- -
- -

Company Description

CEO
Zhao Wu Leng
Full Time Employees
810
Sector
Distribution services
Industry
Medical distributors
Address
Shanghai China
IPO Date
Dec 28, 2021
Business
Shanghai Universal Biotech Co., Ltd. is a China-based life science platform enterprise engaged in the research, development, supply, and provision of comprehensive biotechnology research reagents, laboratory consumables, analytical instruments, and contract experimental services. Founded in 2004 and headquartered in Shanghai, China, the company operates as a one-stop procurement and solutions provider serving academic universities, scientific research institutes, medical centers, hospitals, contract research organizations, biopharmaceutical enterprises, and in vitro diagnostic manufacturers across domestic and international markets. The company delivers an integrated product and service portfolio organized across core life science research categories, including: life science research reagents, comprising primary and secondary antibodies, recombinant proteins, biochemical reagents, molecular biology kits, cell culture media, and enzyme-linked immunosorbent assay (ELISA) kits; laboratory consumables, such as cell culture plates, dishes, flasks, pipette tips, filtration units, PCR plasticware, and cryopreservation containers; laboratory instruments and equipment, featuring flow cytometers, microplate readers, Western blot imaging systems, automated liquid handlers, centrifuges, and benchtop analytical devices; and technical and experimental research services, including custom antibody preparation, flow cytometry testing, proteomics analysis, immunohistochemistry (IHC) services, multi-omics assay support, and single-cell sequencing services. The company supplies its catalog through an extensive network of international brand distributions alongside proprietary brand labels, including Univ and Absin. In recent developments, Shanghai Universal Biotech Co., Ltd. has accelerated the strategic expansion of its proprietary research and development capabilities, substantially increasing the scale and variety of its self-developed antibody products, molecular diagnostic reagents, and specialty biochemicals to enhance supply independence. The company has expanded its technical service segment by launching advanced service platforms dedicated to spatial multi-omics, high-throughput flow cytometry screening, and recombinant antibody engineering. Furthermore, the company has strengthened its nationwide supply chain infrastructure through the continuous optimization of regional temperature-controlled cold-chain logistics centers across major Chinese biomedical clusters, upgraded its proprietary e-commerce and digital procurement platform (Univ-Mall), and established collaborative strategic supply agreements with life science component manufacturers to extend product availability and broaden market coverage.